It is the letter every cancer patient and their family has been waiting for. On Saturday, the National Pharmaceutical Pricing Authority formally notified its long-promised price cut on cancer medicines, publishing the final list of 137 anti-cancer drugs whose trade margins will be capped at 30 per cent of the maximum retail price. The revised prices kick in on November 9, and for many treatments the bill could shrink by up to 70 per cent.
The notification, issued under Paragraph 19 of the Drugs (Prices Control) Order, 2013, turns an October 8 in-principle decision into enforceable law. It follows weeks of sharp questioning from the Supreme Court, which had pulled up hospitals and the pharmaceutical industry over inflated prices for life-saving medicines.
What exactly has changed
The cap applies to the trade margin, the gap between the price at which a medicine is supplied in the market and the MRP printed on the pack. Until now, an NPPA analysis found that non-scheduled anti-cancer medicines carried an average trade mark-up of around 170 per cent, with some formulations marked up by 700 per cent or more. The new rule restricts that margin to 30 per cent of the MRP, excluding GST.
Because the starting mark-ups vary so widely, the savings will not be uniform. Depending on the existing price structure of each formulation, MRPs are expected to fall broadly in the range of 20 to 70 per cent. The government estimates the measure will save patients around Rs 2,500 crore every year, out of a non-scheduled anti-cancer drug market worth roughly Rs 12,500 crore.
Which drugs are on the list
The 137 formulations were recommended by an expert committee under the Directorate General of Health Services that brought together leading oncologists, medical specialists, hospital experts and government officials. The list covers immunotherapy drugs used to treat more than 20 types of cancer, along with widely used names such as Bevacizumab, Atezolizumab, Durvalumab, Osimertinib, Denosumab, Daratumumab, Erlotinib and Ipilimumab.
Denosumab, used by breast and prostate cancer patients, and Pegfilgrastim, which prevents neutropenia in patients undergoing chemotherapy, also figure on the list. The cap applies irrespective of strength, dosage form or route of administration, including combination formulations containing the listed drugs. The health ministry has said the list will be reviewed and updated periodically.
What hospitals and chemists must do
The notification does not leave implementation to chance. Drugmakers have been directed to publish revised price lists on their official websites and circulate them among retailers and hospitals. Retailers and hospitals must charge the reduced rates from November 9 and display the revised prices in their pharmacies. Hospitals, which directly procure a large share of oncology medicines, will also have to show the new rates on their websites and take direct responsibility for implementing them.
State drug controllers have been told to enforce compliance across manufacturers, dealers, retailers, hospitals and medical institutions. Manufacturers must also maintain current production levels, a safeguard meant to ensure the price cut does not lead to artificial shortages.
How patients can check what they should pay
For families, the most practical tool is the one the NPPA itself recommends. Consumers can verify updated drug rates on the NPPA website and through the government’s ‘Pharma Sahi Daam’ mobile app, which lets users check whether the price they are being charged matches the notified MRP.
Patient advocacy groups have long advised buyers to insist on a printed bill and to compare the pack price against the notified list, since overcharging has often happened silently at hospital pharmacies.
Why the government says this works
The Department of Pharmaceuticals points to its 2019 pilot as proof. That exercise capped trade margins on 42 anti-cancer medicines at 30 per cent and led to MRP reductions of up to 90 per cent across 526 brands. The court pressure behind the move has not gone away either: the bench of Justices Vikram Nath and Sandeep Mehta has repeatedly asked why price regulation should stop at cancer drugs, and the petitions seeking wider price controls are still being heard.
Frequently asked questions
From which date will cancer drug prices fall?
Retailers and hospitals must charge the revised, lower rates from November 9, 2026. Prices before that date are governed by the old MRPs.
How much cheaper will the medicines get?
Reductions are expected to range between 20 and 70 per cent depending on the formulation’s existing mark-up. There is no flat 70 per cent discount on every drug.
Are all cancer medicines covered?
No. Only the 137 non-scheduled anti-cancer formulations notified by the NPPA are covered. Scheduled cancer drugs already fall under the price-control framework.
Where can I check the new price of my medicine?
On the NPPA website and the ‘Pharma Sahi Daam’ mobile app. Drugmakers must also publish revised price lists on their own websites.
What if a hospital charges more than the new MRP?
State drug controllers have been directed to enforce the notification. Patients can report overcharging to the state drug controller in their state.
Cancer remains one of the most financially devastating illnesses an Indian family can face, and for years the biggest relief on drug prices was stuck in committee rooms and courtrooms. With the final notification now on the books and a hard date on the calendar, the next test is the one that matters most: whether the new MRPs actually show up on pharmacy bills from November 9.
